C20H26O4 · MW ≈ 330.42 · CAS 31932-13-5 · non-intoxicating raw acid · acid of CBDV · decarboxylates to CBDV (near-complete 130 °C / 30 min, verified) · from the varin mother acid CBGVA
40 questions are answered here. 23 carry a verified grade on the six-rung evidence ladder. 13 are marked with an evidence state rather than a rung — most often no primary evidence, which means our registry holds nothing on that question. That is not the same claim as not supported, and we do not render it as one. The remaining 4 carry an author qualifier that is not yet part of the controlled vocabulary, so they are shown without a grade chip rather than with a guessed one — catalogue in progress.
Verified science — what CBDVA *is*, its formula/CAS, how it forms, that it decarboxylates to CBDV, and that the raw acid is non-intoxicating — is stated as fact with a grade. Any effect or benefit is **reported as a third-party claim** and paired with the honest limit; **CBG Atlas does not make, adopt, or affirm these claims**. Where evidence is thin we say "catalogue in progress." Not medical or legal advice.
CBDVA (cannabidivarinic acid) is the raw, non-intoxicating acid form of CBDV (cannabidivarin), found in living cannabis. On heating, CBDVA decarboxylates to CBDV. That chemistry is Established. CBDVA's own effects in people are a separate matter: no controlled human study of CBDVA has been published, so this is untested rather than tested-and-null, and everything past the chemistry is catalogue in progress.
CBDVA stands for cannabidivarinic acid — the carboxylic-acid ("-ic acid") form of cannabidivarin (CBDV), which is itself the varin (propyl) homolog of CBD. The "A" marks the acid group the living plant makes first. Its formula is C20H26O4, molecular weight ≈ 330.42, CAS 31932-13-5. The name describes chemistry, and that chemistry is Established; it implies no effect.
CBDVA sits on the varin branch of biosynthesis: the varin "mother acid" CBGVA is converted by a synthase enzyme into CBDVA, paralleling how CBGA yields CBDA in the main pentyl line. Heating CBDVA then decarboxylates it to the neutral CBDV.
Yes — CBDVA is a naturally occurring cannabinoid acid present in raw, unheated cannabis, especially varin-rich chemotypes. CBDVA is the form the living plant makes; the neutral CBDV appears mainly after heating, drying, or aging drives off CO₂. CBDVA can also be prepared as a laboratory reference standard, but the molecule in hemp is plant-made. Established plant chemistry.
No. As a raw cannabinoid acid, CBDVA is non-intoxicating — cannabinoid acids don't activate the CB1 receptor the way THC does. Its heated product, CBDV, is also non-intoxicating. There is no verified evidence that CBDVA produces any high in people.
No — CBDVA is not known to be intoxicating, and its heated form CBDV is non-intoxicating too. Whether the raw acid has any subtle psychoactive effect is genuinely unstudied rather than studied-and-ruled-out: no controlled human data on CBDVA exist in either direction. That half of the question stays catalogue in progress, and we would rather say so than guess.
CBDVA's effects in the body are not established. The one verified in-vitro handle for cannabinoid acids as a class is inhibition of the enzyme DAGLα (De Petrocellis 2011, PMID 21175579) — a cell-level finding, not a human effect. Catalogue in progress.
Unheated, CBDVA is a non-intoxicating acid whose specific activity in people is unverified. Some "raw cannabinoid" interest exists, but CBDVA's raw effects are not established (not medical advice). To obtain neutral CBDV, the acid must be decarboxylated with heat. Catalogue in progress.
Legality depends on source and jurisdiction, not the molecule alone. Where hemp-derived cannabinoids under 0.3% Δ⁹-THC are permitted, CBDVA generally falls in that framework; elsewhere it may be restricted. This is a general, dated snapshot (2026-07-11), not legal advice — verify locally.
Generally yes, with one important limit. In the US, hemp-derived CBDVA in a product at or below 0.3% Δ⁹-THC by dry weight is generally federally legal as a hemp product under the 2018 Farm Bill — but the FDA has not authorised cannabinoids as foods or dietary supplements, so a lawful hemp derivative is not automatically a lawful food ingredient. Dated 2026-07-11; general information, not legal advice.
CBDVA's status depends on your state, and we cannot determine that for you here. US state laws vary, and some restrict hemp cannabinoids more tightly than federal law. CBDVA is essentially never named specifically in statute, so it usually inherits your state's general hemp and THC rules. Check your state's current statute, or ask a qualified attorney. Dated 2026-07-11; informational only, not legal advice.
Generally no — not as a food or supplement you can freely sell. The EU and UK classify extracted cannabinoids as novel foods requiring authorisation, and CBDVA is not specifically authorised; Canada regulates isolated phytocannabinoids under the Cannabis Act. Rules differ by product class and change often, so verify the current national position before relying on this. Dated 2026-07-11; general information, not legal advice.
None are established. CBDVA has no verified human or preclinical evidence for any benefit. Note: its neutral form CBDV has been explored in external epilepsy/autism research, but that is CBDV — not CBDVA — and efficacy is not established (not medical advice). Catalogue in progress.
CBDVA is used mainly as a raw-cannabinoid or full-spectrum ingredient and as a research/reference compound; it has no established therapeutic use. Its main practical role is biochemical — the acid precursor that becomes CBDV when heated (not medical advice). Catalogue in progress.
No effects are established for CBDVA in people. Verified data are limited to in-vitro acid observations (e.g., DAGLα inhibition, De Petrocellis 2011). External research on the neutral CBDV (e.g., seizures) exists but is unproven and about a different molecule (not medical advice). Catalogue in progress.
No — CBDVA itself has never been tested in a controlled human trial. That is an absence of testing, not a test that returned negative: nobody has run the study, so nothing has been found for or against CBDVA in a person, and its human safety and efficacy stay catalogue in progress. CBDV, its decarboxylated form, has been studied and did not establish efficacy — but CBDV is a different molecule and its record does not transfer to the acid.
CBDVA's safety is not established — there are no human safety studies of CBDVA, no defined dose, and no long-term data. Untested is the honest word: nobody has looked, so this is an open question rather than a clean bill of health, and non-intoxicating does not mean proven safe. Consult a qualified professional before use, especially alongside other medications. Catalogue in progress. (Not medical advice.)
CBDVA's side-effect profile is unknown; no controlled studies document its adverse effects, and absence of data isn't evidence of safety. Products may contain other cannabinoids or contaminants. Stop use and seek advice if you feel unwell (not medical advice). Catalogue in progress.
No safe or effective CBDVA dose has been established, so "too much" can't be defined from evidence, and no overdose data exist. As with any unstudied compound, more is not better. This is not dosing or medical advice. Catalogue in progress.
CBDVA-specific interaction data do not exist. Generally, cannabinoids can affect drug-metabolizing enzymes, so interactions are plausible but unverified for CBDVA. If you take any medication — especially seizure medication, given CBDV's research context — consult a clinician or pharmacist first (not medical advice). Catalogue in progress.
Probably not. Standard drug tests screen for THC's metabolite (THC-COOH), not CBDVA, and CBDVA does not convert to THC, so direct interference is unlikely. The real variable is any trace THC in a hemp product. CBDVA-specific cross-reactivity data are limited, so a current third-party certificate of analysis is the only way to see what a product actually contains.
No. CBDVA is not THC and does not decarboxylate into THC — heating CBDVA yields non-intoxicating CBDV, and pure CBDVA contains no THC at all. That much is Established chemistry. The product is the variable: hemp-derived goods can carry trace Δ⁹-THC unless made from isolate, so read the batch certificate of analysis (COA) rather than the front label.
CBDVA is not what drug tests detect and doesn't form THC, so it is unlikely to be the direct cause of a failed test. The real risk is trace THC in a hemp product. If drug-tested, choose products with a COA showing non-detectable THC.
CBDVA appears mostly in raw or full-spectrum hemp preparations and as a reference isolate, since heating converts it to CBDV. It may be used sublingually or within a raw-cannabinoid blend. These are format notes only — CBDVA has no studied route or dose (not medical advice).
CBDVA is rare, so products are limited: some raw or full-spectrum extracts, varin-focused blends, and reference isolates for laboratories. Standalone consumer CBDVA products are uncommon, and any heated product will have converted its CBDVA to CBDV. Potency and purity vary widely between sellers, so a current third-party certificate of analysis (COA) is the only reliable way to know what is actually in the bottle.
There is no established dose for CBDVA. No clinical studies define a safe or effective amount, so CBG Atlas gives no dosing guidance. Any label amount reflects manufacturer choice, not evidence. Consult a qualified professional (not medical or dosing advice). Catalogue in progress.
To become CBDV, yes — CBDVA must be heated (decarboxylated) to lose CO₂, and around 130 °C for roughly 30 minutes converts CBDVA to CBDV near-completely. Kept raw and cold, CBDVA stays a non-intoxicating acid whose own effects are untested rather than tested-and-null. So heat guarantees the chemical conversion; it does not guarantee any benefit, and that side of the question is catalogue in progress.
CBDVA is the raw plant acid; CBDV is its heated, decarboxylated (neutral) form. Both are non-intoxicating. They differ by a single carboxyl group, lost as CO₂ when CBDVA is heated (near-complete around 130 °C/30 min). CBDV is somewhat more studied than the acid.
Both are non-intoxicating cannabinoid acids that decarboxylate on heating, but CBDVA is the varin (propyl) acid that yields CBDV, while CBDA is the pentyl acid that yields CBD. They differ only by side-chain length, and each becomes its own distinct neutral cannabinoid.
CBDVA, THCVA, and CBGVA are the three varin acids, and CBGVA is their shared mother acid, branching into CBDVA (→CBDV) and THCVA (→THCV). Set against the pentyl acids (CBGA, CBDA, THCA, CBCA), they share the same acid chemistry but carry propyl side chains two carbons shorter. All are non-intoxicating in raw form. That relationship is Established; what any of them does in a person is a separate, largely untested question.
"Raw" means the acid CBDVA is intact and non-intoxicating; "decarbed" means heat has removed its carboxyl group and left neutral CBDV. CBDVA and CBDV are chemically distinct molecules, and only decarbed material is CBDV — an Established relationship. Neither one is an approved or established treatment for anything, and CBDVA's own human evidence is catalogue in progress. (Not medical advice.)
CBDVA's molecular formula is C20H26O4 (molecular weight ≈ 330.42 g/mol), CAS 31932-13-5. Structurally, CBDVA is the carboxylic-acid precursor of CBDV (C19H26O2) and the varin analog of CBDA, carrying a carboxyl group that neutral CBDV lacks. Heating removes that group as CO₂ to give CBDV. This chemical identity is Established; CBDVA's biological effects are a separate, largely unstudied question.
CBDVA is obtained from raw, unheated varin-rich cannabis using gentle, heat-avoiding extraction — heat converts CBDVA to CBDV — followed by chromatographic purification. Because plants make very little of it and heat destroys the acid, isolating stable CBDVA is low-yield and technically demanding, which is much of why finished CBDVA products are rare. The extraction chemistry itself is Established.
Yes. In biosynthesis, the varin mother acid CBGVA is the precursor, and a synthase enzyme converts it into CBDVA (one branch), just as CBGA yields CBDA in the pentyl line. The specific varin synthases are less characterized — catalogue in progress for that step.
CBDVA decarboxylates to CBDV with gentle heat over time; around 130 °C for ~30 minutes gives near-complete conversion — a directly verified condition for this acid. Roughly 110 °C works more slowly; hotter (150–160 °C) is faster but risks degradation.
CBDVA is sold by a small number of specialty hemp/cannabinoid and reference-chemical suppliers, usually as raw-cannabinoid extracts or reference isolates. It is niche and inconsistently stocked. CBG Atlas endorses no specific brand — buy only from vendors that publish third-party lab results.
CBDVA occurs only in specific varin-rich chemotypes and in small amounts, and it converts to CBDV with heat, so isolating stable CBDVA is low-yield and technically demanding. Cold handling, cold storage, and extra purification all add cost. Scarcity plus specialised handling is what makes CBDVA rare and expensive next to common cannabinoids like CBD — scarcity is a supply fact, not a sign of potency.
Request a current certificate of analysis (COA) from an accredited third-party lab confirming CBDVA content, showing the THC level, and screening for pesticides, solvents, and heavy metals. The label should match the COA. No COA, or a mismatched one, is a red flag.
That is your call, and the honest input is this: CBDVA has no established benefit and has never been tested in a controlled human trial, so any value is speculative rather than evidence-based — untested, not tested-and-rejected. Catalogue in progress. If you do try it, prioritise lab-tested products with a current certificate of analysis and keep expectations proportionate to the evidence. (Not medical advice.)
Look for a third-party COA matching the label, compliant and clearly declared THC, stated cannabinoid amounts, contaminant screening, and transparent sourcing. Be sceptical of health claims, especially seizure-related ones borrowed from CBDV research: none is verified for CBDVA, whose evidence file is catalogue in progress rather than positive. Testing and transparency are the only things you can actually check at the point of purchase. (Not medical advice.)
CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Statements about effects, benefits or uses reflect claims made by third parties — CBG Atlas does not make, adopt or affirm them. Legal status is scoped to jurisdiction, product class and date, and moves; verify against the official source. See how we grade and the safety page. Peregrine Biopharma funds the platform and holds no editorial authority.